SEATTLE – October 27, 2025 –Leaders in HIV research highlighted the critical role of that research has played in advancing HIV science over the past 40 years. In a commentary in Nature Medicine, they ...

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced its program for the upcoming 25th International AIDS Conference (AIDS 2024), taking place in Munich, Germany ...

After four decades of hard-won progress toward curbing the HIV epidemic, the face of the disease is changing.

The global Kaposi’s Sarcoma market is expanding due to the HIV/AIDS prevalence, improved oncology infrastructure, and advancements in targeted and immunotherapeutic drugs. Kaposi’s Sarcoma, a tumor ...

Opinion: "While the obstacles we face may be significant, Lenacapavir represents a monumental breakthrough in the fight ...

Termination of HIV vaccine studies affects key research institutions, aligning with previous cuts to HIV-related programs under the Trump administration. The administration plans to focus on existing ...

The key theme of the 20th International AIDS Conference, which recently concluded in Melbourne, Australia, was "stepping up the pace" to broaden global access to HIV testing and treatment, but ...

– Investigational Long-Acting, Twice-Yearly Treatment Regimen of Lenacapavir and Broadly Neutralizing Antibodies (bNAbs) Meets Primary Endpoint in Phase 2 Study and Gains Breakthrough Therapy ...

The start of AIDS Awareness Month puts a spotlight on how treatment for HIV and AIDS has progressed over the past 40 years. Treatment for HIV/AIDS has consistently seen progress each decade, since the ...

The 22nd Conference on Retroviruses and Opportunistic Infections that took place last month in Seattle is one of the largest scientific conferences on HIV and hepatitis C virus (HCV) research in the ...

LONDON (Reuters) - Treating people with HIV rapidly after they have become infected with the virus that causes AIDS may be enough to achieve a "functional cure" in a small proportion of patients ...